Lexeo Therapeutics, Inc. $LXEO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 82,046,255 [10-Q 2026-08-12]
What the company doesAI summary of filing
The provided text does not contain Item 1 (Business). Only the table of contents and forward-looking statements section are included, which reference product candidates LX2006 and LX2020 and mention preclinical and clinical trial activities, but do not describe the company's actual business operations. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$46.06M | −$38.74M | $92.83M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$100.00M | −$98.56M | $63.00M | [10-Q 2026-08-12] |
| FY ended Dec 2024 | — | −$98.33M | −$81.15M | $35.01M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$19.37M
- Cash runway Estimate
- ~14.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 33,065,947 | [10-Q 2024-11-13] |
| 2025-03-21 | 33,196,997 | [10-K 2025-03-24] |
| 2025-05-09 | 33,196,997 | [10-Q/A 2025-05-15] |
| 2025-08-12 | 54,001,214 | [10-Q 2025-08-14] |
| 2025-11-03 | 72,987,327 | [10-Q 2025-11-05] |
| 2026-03-27 | 74,087,063 | [10-K 2026-03-30] |
| 2026-05-07 | 78,521,634 | [10-Q 2026-05-11] |
| 2026-08-10 | 82,046,255 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-11-05; declared effective 2025-11-26 [S-3 2025-11-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Bhalla Narinder Pal | grant | 2,714 | $3.58 | [4 2026-09-28] |
| 2026-09-14 | Otero Jose Manuel | grant | 2,110 | $2.64 | [4 2026-09-28] |
| 2026-09-14 | Townsend Richard Nolan | grant | 2,306 | $2.64 | [4 2026-09-28] |
| 2026-08-18 | Tamayo Louis Edward | sell | 4,117 | $4.91 | [4 2026-08-19] |
| 2026-08-18 | Townsend Richard Nolan | sell | 3,345 | $4.95 | [4 2026-08-19] |
| 2026-08-18 | Otero Jose Manuel | sell | 1,304 | $4.96 | [4 2026-08-19] |
| 2026-07-01 | Tamayo Louis Edward | sell | 4,641 | $4.49 | [4 2026-07-01] |
| 2026-06-29 | Tamayo Louis Edward | grant | 12,000 | — | [4 2026-07-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Acquisition or disposition completed; Unregistered sale of equity |
| 2026-09-22 | 8-K | Material agreement entered; Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Other events |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-29 | 8-K | Shareholder vote results |
| 2026-06-15 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $LXEO
Email me when Lexeo Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.